LT2646470T - Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą - Google Patents

Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą

Info

Publication number
LT2646470T
LT2646470T LTEP11794336.5T LT11794336T LT2646470T LT 2646470 T LT2646470 T LT 2646470T LT 11794336 T LT11794336 T LT 11794336T LT 2646470 T LT2646470 T LT 2646470T
Authority
LT
Lithuania
Prior art keywords
brain barrier
low affinity
blood brain
transferrin receptor
receptor antibodies
Prior art date
Application number
LTEP11794336.5T
Other languages
English (en)
Inventor
Mark Dennis
Ryan Jefferson Watts
Yunhua Joy Yu
Yin Zhang
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45316102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2646470(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of LT2646470T publication Critical patent/LT2646470T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
LTEP11794336.5T 2010-11-30 2011-11-29 Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą LT2646470T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41822310P 2010-11-30 2010-11-30
PCT/US2011/062445 WO2012075037A1 (en) 2010-11-30 2011-11-29 Low affinity blood brain barrier receptor antibodies and uses therefor

Publications (1)

Publication Number Publication Date
LT2646470T true LT2646470T (lt) 2017-06-12

Family

ID=45316102

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11794336.5T LT2646470T (lt) 2010-11-30 2011-11-29 Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą

Country Status (34)

Country Link
US (5) US20120171120A1 (lt)
EP (2) EP3208282A1 (lt)
JP (3) JP6125430B2 (lt)
KR (3) KR102099462B1 (lt)
CN (2) CN110251668A (lt)
AR (1) AR084020A1 (lt)
AU (2) AU2011336716B2 (lt)
BR (1) BR112013013083A2 (lt)
CA (1) CA2818173C (lt)
CL (1) CL2013001535A1 (lt)
CO (1) CO6721052A2 (lt)
CR (1) CR20130255A (lt)
CY (1) CY1118906T1 (lt)
DK (1) DK2646470T3 (lt)
EA (1) EA034333B1 (lt)
EC (1) ECSP13012724A (lt)
ES (1) ES2631356T3 (lt)
HR (1) HRP20170590T1 (lt)
IL (1) IL282877A (lt)
LT (1) LT2646470T (lt)
MA (1) MA34749B1 (lt)
MX (1) MX358367B (lt)
MY (1) MY188469A (lt)
NZ (2) NZ724348A (lt)
PE (1) PE20140981A1 (lt)
PL (1) PL2646470T3 (lt)
PT (1) PT2646470T (lt)
RS (1) RS55920B1 (lt)
SG (1) SG190900A1 (lt)
SI (1) SI2646470T1 (lt)
TW (3) TW201305200A (lt)
UA (1) UA117801C2 (lt)
WO (1) WO2012075037A1 (lt)
ZA (1) ZA201303572B (lt)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285763B2 (en) 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2182980A4 (en) 2007-07-27 2012-04-18 Armagen Technologies Inc METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
PE20140238A1 (es) 2010-11-10 2014-03-07 Genentech Inc Metodos y composiciones para inmunoterapia para enfermedad neural
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112014028838A2 (pt) * 2012-05-21 2020-05-12 Genentech Inc Usos de um anticorpo, método para fazer um anticorpo e anticorpos
EP3138580B1 (en) 2012-07-04 2021-03-03 F. Hoffmann-La Roche AG Covalently linked antigen-antibody conjugates
KR20190121874A (ko) * 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
BR112015012014A2 (pt) * 2012-12-04 2017-07-11 Abbvie Inc proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
PL3594240T3 (pl) * 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
EP3730516A1 (en) * 2013-07-22 2020-10-28 Armagen, Inc. Methods and compositions for increasing enzyme activity in the cns
BR112016001782A2 (pt) * 2013-08-02 2017-08-29 Hoffmann La Roche Proteína de fusão terapêutica
BR112016004413A2 (pt) 2013-09-13 2017-10-17 Genentech Inc composições, preparação de anticorpo e método de purificação de um polipeptídeo recombinante e de tratamento de um distúrbio
BR112016004437A2 (pt) 2013-09-13 2017-10-17 Genentech Inc métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
RU2697098C1 (ru) * 2013-11-21 2019-08-12 Ф.Хоффманн-Ля Рош Аг Антитела к альфа-синуклеину и способы применения
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
CN105829542A (zh) 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 改进的重组多肽生产方法
EP3450557A1 (en) 2013-12-25 2019-03-06 JCR Pharmaceuticals Co., Ltd. Novel anti-transferrin receptor antibody that passes through blood-brain barrier
CN105873615B (zh) 2014-01-03 2020-12-25 豪夫迈·罗氏有限公司 共价连接的helicar-抗helicar抗体缀合物及其用途
JP6476194B2 (ja) * 2014-01-03 2019-02-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗ハプテン／抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
CN105873616B (zh) 2014-01-03 2020-06-05 豪夫迈·罗氏有限公司 共价连接的多肽毒素-抗体缀合物
MX2016008190A (es) 2014-01-06 2016-10-21 Hoffmann La Roche Modulos de lanzadera de barrera cerebral sanguinea monovalente.
CA2942152C (en) 2014-03-06 2023-08-01 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
JP6541237B2 (ja) * 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP6541236B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015175375A1 (en) 2014-05-13 2015-11-19 Short Jay M Conditionally active biological proteins
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
EP4074735A1 (en) 2014-08-28 2022-10-19 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
EP3218411B1 (en) 2014-11-14 2022-01-12 Ossianix, Inc. Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use
EP3221361B1 (en) * 2014-11-19 2021-04-21 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
EP3221364B1 (en) 2014-11-19 2020-12-16 Genentech, Inc. Antibodies against bace1 and use thereof for neural disease immunotherapy
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
MX2017012966A (es) 2015-04-10 2018-06-06 Amgen Inc Muteinas de interleuquina 2 para la expansion de celulas t regulatorias.
MX2017014139A (es) 2015-05-04 2018-07-06 Cytomx Therapeutics Inc Anticuerpos anti-cd71, anticuerpos anti-cd71 activables, y metodos de uso de los mismos.
CN107847588B (zh) 2015-05-20 2021-12-28 免疫功坊股份有限公司 具有靶向部分及效应部分的分子构建体及其应用
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3315515A4 (en) 2015-06-24 2019-06-05 JCR Pharmaceuticals Co., Ltd. HYBRID PROTEIN CONTAINING A BDNF
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
KR20180020277A (ko) 2015-06-24 2018-02-27 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 항인간 트랜스페린 수용체 항체
ES2908009T3 (es) * 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
JP6657392B2 (ja) * 2015-10-02 2020-03-04 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法
EP3454901A4 (en) * 2016-05-09 2020-07-29 Annexon, Inc. COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE SPINAL AMYOTROPHY
HRP20221298T1 (hr) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
CA3028035A1 (en) 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
AU2017311040B2 (en) 2016-08-06 2023-08-31 Ossianix, Inc. In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
CN106442967B (zh) * 2016-09-27 2018-05-15 鸿运华宁（杭州）生物医药有限公司 一种检测跨膜蛋白单克隆抗体亲和力的方法
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
IL266156B1 (en) 2016-12-26 2024-01-01 Japan Chem Res A new antibody against the human transferrin receptor, capable of penetrating the blood-brain barrier
JP7072524B2 (ja) 2016-12-26 2022-05-20 Ｊｃｒファーマ株式会社 Ｂｄｎｆを含む融合蛋白質
NZ756763A (en) 2017-02-17 2023-04-28 Denali Therapeutics Inc Engineered transferrin receptor binding polypeptides
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US10363245B2 (en) 2017-02-22 2019-07-30 The Board Of Regents Of The University Of Texas System Methods for treating CNS lesions
AU2018312441A1 (en) * 2017-08-02 2020-02-06 Stressmarq Biosciences Inc. Antibody binding active alpha-synuclein
EP3438128B1 (en) * 2017-08-04 2020-05-20 Alzheimur 2012 S.L. Anti-presenilin antibody for use in the prevention and/or treatment of cancer
CN111148757A (zh) * 2017-08-10 2020-05-12 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
EP3694875A1 (en) 2017-10-09 2020-08-19 Wisconsin Alumni Research Foundation Antibodies targeting glioblastoma stem-like cells and methods of use thereof
EP3704149A1 (en) 2017-11-02 2020-09-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
US20200399623A1 (en) 2018-02-07 2020-12-24 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019243502A1 (en) 2018-06-21 2019-12-26 Novo Nordisk A/S Novel compounds for treatment of obesity
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3108282A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2020056327A1 (en) 2018-09-14 2020-03-19 Ossianix, Inc. Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
KR20200047937A (ko) * 2018-10-26 2020-05-08 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
TW202039581A (zh) * 2018-12-28 2020-11-01 日商協和麒麟股份有限公司 與TfR結合之雙專一性抗體
AU2020206593A1 (en) 2019-01-09 2021-07-15 Centre National De La Recherche Scientifique Transferrin receptor-binding molecules, conjugates thereof and their uses
CN116063505A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
CN114829586A (zh) 2019-08-14 2022-07-29 科迪亚克生物科学公司 细胞外囊泡-nlrp3拮抗剂
WO2021030780A1 (en) 2019-08-14 2021-02-18 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CA3147680A1 (en) 2019-08-14 2021-02-18 Dalia BURZYN Extracellular vesicle-aso constructs targeting stat6
US20230018254A1 (en) 2019-08-14 2023-01-19 Codiak Biosciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
CA3147366A1 (en) 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
JP2022547297A (ja) 2019-09-09 2022-11-11 エフ．ホフマン－ラ ロシュ アーゲー グルコセレブロシダーゼ変異体
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
TWI739220B (zh) * 2019-11-26 2021-09-11 亞瑟瑞智科技管理顧問股份有限公司 包含克拉維酸與丙戊酸之組合物及其用途
IL293994A (en) 2019-12-23 2022-08-01 Denali Therapeutics Inc Variants of progranulin, preparations containing them and their uses
CA3163283A1 (en) * 2020-01-10 2021-07-15 Romesh R. Subramanian Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health
WO2021146218A1 (en) * 2020-01-13 2021-07-22 Truebinding, Inc. Anti-gal3 antibodies and methods of use
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
IL305171A (en) 2021-02-17 2023-10-01 Lonza Sales Ag EXTRACELLULAR VESILE-NLRP3 antagonist
CN117693531A (zh) 2021-06-11 2024-03-12 生命北极公司 双特异性结合分子
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
IL311175A (en) 2021-09-01 2024-04-01 Biogen Ma Inc Anti-transferrin receptor antibodies and their uses
WO2023166168A1 (en) 2022-03-03 2023-09-07 Vib Vzw Polystyrene sulfonate for use to treat neurodegenerative diseases
WO2023198661A1 (en) 2022-04-12 2023-10-19 F. Hoffmann-La Roche Ag Fusion proteins targeted to the central nervous system
US11931421B2 (en) 2022-04-15 2024-03-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS55113334A (en) 1979-02-23 1980-09-01 Hitachi Ltd Manufacture of passivation film
US4332785A (en) 1980-04-09 1982-06-01 University Patents, Inc. Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein
US4447547A (en) 1980-04-09 1984-05-08 University Patents, Inc. Immunoassay for measurement of reticulocytes, and immunoreactive reagents for use therein
US4626507A (en) 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US4434156A (en) 1981-10-26 1984-02-28 The Salk Institute For Biological Studies Monoclonal antibodies specific for the human transferrin receptor glycoprotein
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
JPS6210017A (ja) 1985-07-04 1987-01-19 Mochida Pharmaceut Co Ltd トランスフエリンレセプタ−の精製方法
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4956453A (en) 1985-12-06 1990-09-11 Cetus Corporation Anti-human ovarian cancer immunotoxins and methods of use thereof
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
JP2736255B2 (ja) 1987-03-11 1998-04-02 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー イムノグロブリン結合体
US5352447A (en) 1987-10-05 1994-10-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins for treatment of intracranial lesions and as adjunct to chemotherapy
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5728383A (en) 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5231000A (en) * 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5217713A (en) 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
CA2006408A1 (en) 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
CA2011099A1 (en) 1989-04-19 1990-10-19 Stephen C. Wardlaw Determination of lymphocyte reactivity to specific antigens in blood
US5141743A (en) 1989-04-27 1992-08-25 University Technologies International, Inc. Method for isolating and purifying transferrin and lactoferrin receptor proteins and vaccines containing the same
US5292869A (en) 1989-04-27 1994-03-08 The Board Of Governors Of The University Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US5527527A (en) 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1993010819A1 (en) 1991-11-26 1993-06-10 Alkermes, Inc. Process for the preparation of transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5182107A (en) 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5154924A (en) 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE154245T1 (de) 1990-03-27 1997-06-15 Salk Inst For Biological Studi Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JP3532563B2 (ja) 1990-08-23 2004-05-31 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル Ｎｅｉｓｓｅｒｉａ ｇｏｎｏｒｒｈｏｅａｅおよびＮｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ由来トランスフェリン結合蛋白質
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
JPH04187096A (ja) 1990-11-20 1992-07-03 Takeda Chem Ind Ltd 二重特異性を有するハイブリッド・モノクローナル抗体
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
DE4110409C2 (de) 1991-03-29 1999-05-27 Boehringer Ingelheim Int Neue Protein-Polykation-Konjugate
US6287792B1 (en) 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
ES2265005T3 (es) 1991-07-25 2007-02-01 Biogen Idec Inc. Anticuerpos recombinantes para terapia humana.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5648469A (en) 1992-04-20 1997-07-15 The Salk Institute For Biological Studies Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
WO1994002178A1 (en) 1992-07-27 1994-02-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Targeting of liposomes to the blood-brain barrier
CN1990503A (zh) 1993-11-08 2007-07-04 康诺特实验室有限公司 嗜血杆菌属转铁蛋白受体基因
US6361779B1 (en) 1993-11-08 2002-03-26 Aventis Pasteur Limited Transferrin receptor genes
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6015555A (en) 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
JP3973169B2 (ja) 1995-09-26 2007-09-12 栄研化学株式会社 トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6497881B1 (en) 1995-11-30 2002-12-24 New York University High efficiency tissue specific compound delivery system using streptavidin-protein a fusion protein
AU2112697A (en) 1996-02-09 1997-08-28 Pi-Wan Cheng Receptor ligand-facilitated delivery of biologically active molecules
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6440701B1 (en) 1996-03-08 2002-08-27 Aventis Pasteur Limited Transferrin receptor genes of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
WO1998022092A1 (en) 1996-11-22 1998-05-28 The Regents Of The University Of California Transport of liposomes across the blood-brain barrier
JPH10245400A (ja) 1997-02-28 1998-09-14 Eiken Chem Co Ltd トランスフェリンレセプターの安定化方法
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
CA2322200A1 (en) 1998-02-24 1999-08-26 Receptron, Inc. Receptor derived peptides as modulators of receptor activity
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
EP2180007B2 (en) 1998-04-20 2017-08-30 Roche Glycart AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6891028B1 (en) 1998-11-06 2005-05-10 Cedars-Sinai Medical Center Nucleic acids encoding transferrin receptor-like proteins
WO2000029574A2 (en) 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
AU1628800A (en) 1998-11-19 2000-06-05 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7479276B1 (en) 1999-02-22 2009-01-20 Synergene Therapeutics, Inc. Antibody fragment-targeted immunoliposomes for systemic gene delivery
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
US6511967B1 (en) 1999-04-23 2003-01-28 The General Hospital Corporation Use of an internalizing transferrin receptor to image transgene expression
US6582945B1 (en) 1999-06-16 2003-06-24 Boston Biomedical Research Institute Immunological control of β-amyloid levels in vivo
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
AU6607100A (en) 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
CA2393292A1 (en) 1999-12-13 2001-06-21 Cambridge Antibody Technology Limited Brain specific binding members
AU2001244602A1 (en) 2000-03-30 2001-10-15 Ajinomoto Co. Inc. Drugs retained in target tissue over long time
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001257613A1 (en) 2000-04-23 2001-11-12 Arizeke Pharmaceuticals, Inc. Compositions comprising carriers and transportable complexes
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
GB0027328D0 (en) 2000-06-23 2000-12-27 Aventis Pharma Inc Bioengineered vehicles for targeted nucleic acid delivery
AU2001276018A1 (en) 2000-07-20 2002-02-05 Regents Of The University Of Minnesota Radiolabeled immunotoxins
PT1317479E (pt) 2000-09-06 2009-10-29 Univ Pasteur Métodos e composições para doenças associadas à amiloidose
JP2002095476A (ja) 2000-09-20 2002-04-02 Eisai Co Ltd トランスフェリン受容体を介した遺伝子導入法
US6743893B2 (en) 2000-11-30 2004-06-01 The Uab Research Foundation Receptor-mediated uptake of peptides that bind the human transferrin receptor
WO2002055736A2 (en) 2000-12-04 2002-07-18 Univ California Antisense imaging of gene expression of the brain in vivo
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
AU2002314794A1 (en) 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US20030226155A1 (en) 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
WO2004019872A2 (en) 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
MXPA04003798A (es) 2001-10-25 2004-07-30 Genentech Inc Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8084017B2 (en) 2002-03-07 2011-12-27 Carnegie Mellon University Contrast agents for magnetic resonance imaging and methods related thereto
US7998704B2 (en) 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
AU2003226230A1 (en) 2002-04-02 2003-10-20 Arizeke Pharmaceuticals, Inc. Compositions and methods for targeted biological delivery of molecular carriers
EP1539221B1 (en) 2002-08-30 2009-12-23 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
AU2003262886A1 (en) 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
WO2004062602A2 (en) 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Compositions and methods for targeted biological delivery of molecular carriers
JP4187096B2 (ja) 2003-01-15 2008-11-26 独立行政法人科学技術振興機構 ３次元フォトニック結晶製造方法
JP5036302B2 (ja) * 2003-02-10 2012-09-26 ティオー − ビービービー ホールディング ベスローテン フェンノートシャップ 炎症状態下に血液脳関門で示差的（ｄｉｆｆｅｒｅｎｔｉａｌｌｙ）に発現される核酸
CN1788017B (zh) * 2003-02-10 2013-04-24 to-BBB控股股份有限公司 炎症状态下在血脑屏障中差异表达的核酸
WO2004078777A2 (en) 2003-03-04 2004-09-16 Biorexis Pharmaceutical Corporation Dipeptidyl-peptidase protected proteins
WO2004108071A2 (en) 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
JP2007508806A (ja) 2003-08-04 2007-04-12 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 新規治療融合タンパク質
US20050042298A1 (en) 2003-08-20 2005-02-24 Pardridge William M. Immunonanoparticles
WO2005021579A2 (en) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Epo mimetic peptides and fusion proteins
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
SG10202008722QA (en) 2003-11-05 2020-10-29 Roche Glycart Ag Cd20 antibodies with increased fc receptor binding affinity and effector function
US20050202075A1 (en) 2004-03-12 2005-09-15 Pardridge William M. Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
WO2005094364A2 (en) 2004-03-31 2005-10-13 Chimeric Technologies, Inc. Iga antibody protein as a cytotoxic drug
JP4756032B2 (ja) 2004-03-31 2011-08-24 アトナーゲン アクチエンゲゼルシャフト 胎児赤血球細胞に対して特異性を有するモノクローナル抗体
EP1740616B1 (en) 2004-04-30 2011-12-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-tfr antibody.
AU2005249553B2 (en) 2004-06-02 2010-02-11 Jan E. Schnitzer Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
EP1765868B1 (en) 2004-06-07 2016-04-20 MacroGenics, Inc. Transferrin receptor antibodies
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20090285771A1 (en) 2004-10-04 2009-11-19 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
EP1858546A4 (en) 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp MODIFIED TRANSFERRINFUSION PROTEINS
US9943481B2 (en) 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
JP2005321411A (ja) 2005-06-10 2005-11-17 Eiken Chem Co Ltd トランスフェリン−トランスフェリンレセプター・コンプレックス測定試薬および測定方法
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
CA2611054C (en) 2005-06-17 2017-05-09 National Research Council Of Canada Novel a.beta.-binding polypeptides and derivatives and uses thereof
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
WO2007027559A2 (en) 2005-08-29 2007-03-08 Shashoua Victor E Neuroprotective and neurorestorative methods and compositions
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
WO2007047504A2 (en) 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
EP1971367A4 (en) 2005-12-05 2010-04-07 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR THE NEEDLESS DELIVERY OF BINDING PARTNERS
EP1966246A4 (en) 2005-12-05 2010-01-06 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR NEEDLE-FREE ADMINISTRATION OF ANTIBODIES
EP2808032B1 (en) 2005-12-12 2018-08-01 AC Immune S.A. A beta 1-42 specific monoclonal antibodies with therapeutic properties
WO2007103288A2 (en) 2006-03-02 2007-09-13 Seattle Genetics, Inc. Engineered antibody drug conjugates
US20070231300A1 (en) 2006-03-28 2007-10-04 Washington, University Of Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents
SI2177536T1 (sl) * 2006-03-30 2014-09-30 Glaxo Group Limited Protitelesa proti amiloidnemu peptidu beta
WO2008054544A2 (en) 2006-05-22 2008-05-08 Immune Disease Institute, Inc. Method for delivery across the blood brain barrier
US7744879B2 (en) * 2006-06-07 2010-06-29 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
AU2007277313A1 (en) 2006-07-27 2008-01-31 University Of Virginia Patent Foundation System and method for intracranial implantation of therapeutic or diagnostic agents
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
WO2008021412A2 (en) 2006-08-14 2008-02-21 Biorexis Pharmaceutical Corporation Interferon beta and transferrin fusion proteins
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US8821943B2 (en) 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
WO2008033395A2 (en) 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
EP2089419A2 (en) 2006-10-27 2009-08-19 Zapaloid Limited Inhibition of beta-amyloid aggregation
CN101245107B (zh) * 2007-02-14 2010-10-13 中国人民解放军军事医学科学院生物工程研究所 抗人转铁蛋白受体人源抗体及其应用
EP2124916A1 (en) 2007-02-27 2009-12-02 Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
EP3351270A1 (en) 2007-05-23 2018-07-25 The Trustees of the University of Pennsylvania Targeted carriers for intracellular drug delivery
TWI516500B (zh) 2007-06-12 2016-01-11 Ａｃ免疫公司 抗β類澱粉蛋白單株抗體
ES2529174T3 (es) 2007-06-12 2015-02-17 Ac Immune S.A. Anticuerpos humanizados para amiloide beta
GB0711424D0 (en) 2007-06-13 2007-07-25 Novozymes Delta Ltd Recombinant transferrin mutants
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
GB0725065D0 (en) 2007-12-21 2008-01-30 Got A Gene Ab Method
US8592562B2 (en) 2008-01-07 2013-11-26 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
EP2238162A1 (en) 2008-01-24 2010-10-13 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Induced internalization of surface receptors
KR20100132535A (ko) 2008-03-31 2010-12-17 글락소 그룹 리미티드 약물 융합체 및 컨주게이트
WO2009149281A1 (en) 2008-06-04 2009-12-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins and uses thereof
WO2009155609A1 (en) * 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
US20100077498A1 (en) 2008-09-11 2010-03-25 Pardridge William M Compositions and methods for blood-brain barrier delivery in the mouse
WO2010037135A2 (en) 2008-09-29 2010-04-01 The Regents Of The University Of California Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
US20100098693A1 (en) 2008-10-07 2010-04-22 Pardridge William M Compositions and methods for blood-brain barrier delivery of organophosphatases
JP5851842B2 (ja) 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
WO2010088522A2 (en) * 2009-01-30 2010-08-05 Ab Biosciences, Inc. Novel lowered affinity antibodies and uses therefor
EP2408474B1 (en) 2009-03-18 2019-06-26 Armagen, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
CA2759098A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
JP5944822B2 (ja) * 2009-06-15 2016-07-05 フエー・イー・ベー・フエー・ゼツト・ウエー Ｂａｃｅ１抑制性抗体
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US9149544B2 (en) 2009-11-06 2015-10-06 The Penn State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
FR2953841B1 (fr) 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
AU2010343056A1 (en) 2009-12-29 2012-08-02 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US8734799B2 (en) 2010-04-13 2014-05-27 The Regents Of The University Of California Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer
FR2959416B1 (fr) 2010-05-03 2012-06-22 Monoclonal Antibodies Therapeutics Mat Biopharma Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament
CN110251668A (zh) * 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
JP6210017B2 (ja) 2014-04-17 2017-10-11 マツダ株式会社 自動変速機

Also Published As

Publication number Publication date
CA2818173C (en) 2022-05-03
JP6490721B2 (ja) 2019-03-27
ZA201303572B (en) 2017-06-28
SG190900A1 (en) 2013-07-31
KR20190138314A (ko) 2019-12-12
PT2646470T (pt) 2017-05-03
EP2646470A1 (en) 2013-10-09
DK2646470T3 (en) 2017-05-08
ES2631356T3 (es) 2017-08-30
JP2019116485A (ja) 2019-07-18
US20150329636A1 (en) 2015-11-19
US20120171120A1 (en) 2012-07-05
KR20130137654A (ko) 2013-12-17
MX358367B (es) 2018-08-15
CN110251668A (zh) 2019-09-20
EA201390785A1 (ru) 2013-11-29
TW201305200A (zh) 2013-02-01
AU2016202447B2 (en) 2018-05-17
PE20140981A1 (es) 2014-08-20
CA2818173A1 (en) 2012-06-07
AU2011336716B2 (en) 2016-01-21
HRP20170590T1 (hr) 2017-06-30
US9611323B2 (en) 2017-04-04
PL2646470T3 (pl) 2017-07-31
BR112013013083A2 (pt) 2016-12-13
MY188469A (en) 2021-12-10
US10941215B2 (en) 2021-03-09
IL282877A (en) 2021-06-30
KR102099462B1 (ko) 2020-04-10
TW201801743A (zh) 2018-01-16
NZ706751A (en) 2016-10-28
JP6125430B2 (ja) 2017-05-10
JP2014500886A (ja) 2014-01-16
EP2646470B1 (en) 2017-03-01
CR20130255A (es) 2013-09-18
CN103443125A (zh) 2013-12-11
KR20200038560A (ko) 2020-04-13
TWI689314B (zh) 2020-04-01
EP3208282A1 (en) 2017-08-23
US20170260292A1 (en) 2017-09-14
US20190202936A1 (en) 2019-07-04
WO2012075037A1 (en) 2012-06-07
CO6721052A2 (es) 2013-07-31
KR102188544B1 (ko) 2020-12-08
NZ724348A (en) 2019-12-20
KR102052571B1 (ko) 2019-12-05
RS55920B1 (sr) 2017-09-29
US20210292440A1 (en) 2021-09-23
CL2013001535A1 (es) 2014-03-07
EA034333B1 (ru) 2020-01-29
MX2013005793A (es) 2013-07-22
AR084020A1 (es) 2013-04-17
AU2011336716A1 (en) 2013-05-09
ECSP13012724A (es) 2013-08-30
JP6800260B2 (ja) 2020-12-16
CN103443125B (zh) 2019-05-03
CY1118906T1 (el) 2018-01-10
JP2017105786A (ja) 2017-06-15
MA34749B1 (fr) 2013-12-03
SI2646470T1 (sl) 2017-05-31
UA117801C2 (uk) 2018-10-10
TW202021621A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
LT2646470T (lt) Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
AU2016202447A1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
HK1250733A1 (zh) 抗人il-4受體的高親和性人抗體的製藥用途
ZA201204213B (en) Neutralizing prolacting receptor antibodies and their therapeutic use
IL226399A0 (en) Human antibodies to the glucagon receptor
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
HK1258028A1 (zh) 人類抗體及其在神經疾病治療中的診斷和治療用途
EP2540744A4 (en) TOTALLY HUMAN MONOCLONAL ANTIBODY AGAINST VEGF, PREPARATION METHOD AND APPLICATION THEREOF
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
RS55121B1 (sr) Terapeutska primena proteina ss2-mikroglobulina
IL226635B (en) Human anti-sod1 antibodies